BioWorld

April 16, 2009

View Archived Issues

Sanofi Seeks to Beef Up Cancer Line with BiPar

Paris-based Sanofi-Aventis Group is buying cancer drugmaker BiPar Sciences Inc. in a deal potentially worth $500 million for the Brisbane, Calif.-based firm and its investors. (BioWorld Today) Read More

Lycera Raises $36M Series A for Novel Autoimmune Targets

Read More

Infinity Halts Tumor Trial Due to High Mortality Data

Read More

Synageva Raises $30M to Advance Antibodies Program

Read More

Other News To Note

Read More

Clinic Roundup

Read More